These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37084634)

  • 1. OGFOD1 modulates the transcriptional and proteomic landscapes to alter isoproterenol-induced hypertrophy susceptibility.
    Rodriguez R; Harris M; Murphy E; Kennedy LM
    J Mol Cell Cardiol; 2023 Jun; 179():42-46. PubMed ID: 37084634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ribosomal prolyl-hydroxylase OGFOD1 decreases during cardiac differentiation and modulates translation and splicing.
    Stoehr A; Kennedy L; Yang Y; Patel S; Lin Y; Linask KL; Fergusson M; Zhu J; Gucek M; Zou J; Murphy E
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31112528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ogfod1 deletion increases cardiac beta-alanine levels and protects mice against ischaemia- reperfusion injury.
    Harris M; Sun J; Keeran K; Aponte A; Singh K; Springer D; Gucek M; Pirooznia M; Cockman ME; Murphy E; Kennedy LM
    Cardiovasc Res; 2022 Oct; 118(13):2847-2858. PubMed ID: 34668514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats.
    Chowdhury D; Tangutur AD; Khatua TN; Saxena P; Banerjee SK; Bhadra MP
    J Transl Med; 2013 May; 11():130. PubMed ID: 23706090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.
    Yoshida T; Yamashita M; Horimai C; Hayashi M
    J Biol Chem; 2014 Sep; 289(38):26107-26118. PubMed ID: 25100730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation.
    Singleton RS; Liu-Yi P; Formenti F; Ge W; Sekirnik R; Fischer R; Adam J; Pollard PJ; Wolf A; Thalhammer A; Loenarz C; Flashman E; Yamamoto A; Coleman ML; Kessler BM; Wappner P; Schofield CJ; Ratcliffe PJ; Cockman ME
    Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4031-6. PubMed ID: 24550447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deleting the ribosomal prolyl hydroxylase OGFOD1 protects mice against diet-induced obesity and insulin resistance.
    Rodriguez R; Harris M; Kennedy LM
    PLoS One; 2024; 19(6):e0304761. PubMed ID: 38843265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction.
    Lunardon G; de Oliveira Silva T; Lino CA; Lu YW; Miranda JB; Asprino PF; de Almeida Silva A; Nepomuceno GT; Irigoyen MCC; Carneiro-Ramos MS; Takano APC; Martinho HDS; Barreto-Chaves MLM; Wang DZ; Diniz GP
    Clin Sci (Lond); 2022 Nov; 136(21):1537-1554. PubMed ID: 36285636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoproterenol-induced hypertrophy of neonatal cardiac myocytes and H9c2 cell is dependent on TRPC3-regulated Ca
    Han JW; Kang C; Kim Y; Lee MG; Kim JY
    Cell Calcium; 2020 Dec; 92():102305. PubMed ID: 33069962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OGFOD1, a member of the 2-oxoglutarate and iron dependent dioxygenase family, functions in ischemic signaling.
    Saito K; Adachi N; Koyama H; Matsushita M
    FEBS Lett; 2010 Aug; 584(15):3340-7. PubMed ID: 20579638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase.
    Parreira RC; Gómez-Mendoza DP; de Jesus ICG; Lemos RP; Santos AK; Rezende CP; Figueiredo HCP; Pinto MCX; Kjeldsen F; Guatimosim S; Resende RR; Verano-Braga T
    Proteomics Clin Appl; 2020 Jul; 14(4):e2000017. PubMed ID: 32506788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
    Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
    J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure.
    Galindo CL; Skinner MA; Errami M; Olson LD; Watson DA; Li J; McCormick JF; McIver LJ; Kumar NM; Pham TQ; Garner HR
    BMC Physiol; 2009 Dec; 9():23. PubMed ID: 20003209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the calcium-sensing receptor in cardiomyocyte apoptosis via the sarcoplasmic reticulum and mitochondrial death pathway in cardiac hypertrophy and heart failure.
    Lu FH; Fu SB; Leng X; Zhang X; Dong S; Zhao YJ; Ren H; Li H; Zhong X; Xu CQ; Zhang WH
    Cell Physiol Biochem; 2013; 31(4-5):728-43. PubMed ID: 23711498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Mouse P2Y6 Nucleotide Receptor Is Associated with Physiological Macrocardia and Amplified Pathological Cardiac Hypertrophy.
    Clouet S; Di Pietrantonio L; Daskalopoulos EP; Esfahani H; Horckmans M; Vanorlé M; Lemaire A; Balligand JL; Beauloye C; Boeynaems JM; Communi D
    J Biol Chem; 2016 Jul; 291(30):15841-52. PubMed ID: 27231349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.
    Wang K; Long B; Zhou J; Li PF
    J Biol Chem; 2010 Apr; 285(16):11903-12. PubMed ID: 20177053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.
    Murray DR; Mummidi S; Valente AJ; Yoshida T; Somanna NK; Delafontaine P; Dinarello CA; Chandrasekar B
    J Mol Cell Cardiol; 2012 Jan; 52(1):206-18. PubMed ID: 22004899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.
    Matkovich SJ; Wang W; Tu Y; Eschenbacher WH; Dorn LE; Condorelli G; Diwan A; Nerbonne JM; Dorn GW
    Circ Res; 2010 Jan; 106(1):166-75. PubMed ID: 19893015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy.
    Lu J; Zhang R; Hong H; Yang Z; Sun D; Sun S; Guo X; Ye J; Li Z; Liu P
    Biochim Biophys Acta; 2016 Dec; 1863(12):3027-3039. PubMed ID: 27686254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE3A alleviates isoproterenol-induced cardiac hypertrophy through the inhibition of the TLR4/MMP-9 signaling pathway.
    Li Y; Ma L; Gu S; Tian J; Cao Y; Jin Z; Chen J; Gu B; Tu J; Wang Z; Li X; Ning Z; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):58-63. PubMed ID: 31681945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.